Coagulation testing is often discussed through reagents, analyzers, calibration curves, and turnaround time. Yet many of the most expensive problems begin earlier, before plasma ever reaches the measuring system. A citrate tube that is underfilled, mixed poorly, transported too slowly, centrifuged inconsistently, or stored outside the laboratory’s defined conditions can make a technically sound PT, APTT, fibrinogen, thrombin time, D-Dimer, FDP, or antithrombin assay look unreliable.
This is why the 2024 update of CLSI H21, Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays, is worth attention beyond large reference laboratories. The update reinforces a process view of the preexamination phase: collection, transport, processing, storage, rejection criteria, and troubleshooting all need to work as one controlled workflow. For distributors, OEM partners, and laboratories in developing markets, that message is practical. Reagent performance cannot be separated from specimen discipline.
Preanalytical quality is part of product performance
When a laboratory reports unstable coagulation results, the reagent supplier is often the first person contacted. Sometimes the cause is genuinely related to reagent storage, analyzer settings, calibration, or lot transition. Just as often, the first useful questions are about the specimen. Was the tube filled correctly? Was the citrate concentration appropriate for the laboratory’s procedure? Was the sample mixed immediately after collection? How long did whole blood remain at room temperature? Was plasma separated in time? Were hemolysis, icterus, lipemia, anticoagulant exposure, or other interferences considered?
A strong technical support team treats these questions as normal quality work, not as blame shifting. The goal is to protect the result. Laboratories that serve many collection points, outpatient rooms, or regional hospitals should make preanalytical review part of every new coagulation reagent implementation. This is especially important when moving from basic PT/APTT testing into fibrinogen, D-Dimer, FDP, and antithrombin, where clinical expectations and method-specific behavior may be less familiar to staff.
Citrate tube handling deserves routine training
The citrate tube is a small item, but it controls the starting conditions for plasma-based coagulation assays. Underfilling changes the blood-to-anticoagulant ratio. Poor mixing can allow partial clotting or uneven anticoagulation. Collection through lines, difficult draws, or delayed handling may introduce variables that operators do not see when the sample arrives at the analyzer.
For routine laboratories, the most useful training is concrete. Staff should know the required fill mark, how many gentle inversions are expected by local procedure, when a sample should be rejected, and who has authority to request a redraw. Posters and short collection-room checklists often work better than long manuals. In distributor training, a simple specimen acceptance card can reduce repeated customer complaints more effectively than another reagent brochure.
Transport rules must match real geography
Many coagulation reagent projects fail to plan for the distance between the patient and the analyzer. In a central hospital, specimen transport may take minutes. In a regional network, samples may travel from smaller facilities, sometimes with limited temperature monitoring and uncertain departure times. A written procedure that assumes ideal transport can be unrealistic if it does not match local routes, staffing, and courier schedules.
Before expanding a coagulation menu across several sites, laboratories should map the actual route of the specimen. Who collects it? Where is it held? How is room temperature controlled? When is centrifugation performed? Is plasma transported or whole blood transported? What happens during weekends and holidays? These questions are operational, but they directly affect result confidence.
Suppliers can support this process by helping customers distinguish between reagent storage requirements and specimen transport requirements. Both matter, but they are not the same problem. A well-packed reagent shipment does not compensate for poorly controlled specimen movement inside the customer’s own network.
Processing consistency protects routine assays
Centrifugation and plasma handling are easy to underestimate because they are repeated every day. Small variations in spin time, speed, brake use, plasma transfer, and storage conditions can produce noise that looks like assay instability. For PT and APTT, experienced operators may recognize the pattern quickly. For fibrinogen, D-Dimer, FDP, and antithrombin, the same pattern may be misread as a reagent issue or analyzer issue.
A practical coagulation workflow should define how plasma is prepared, how soon it is tested, and what happens when testing is delayed. Frozen plasma, if used, needs clear rules for freezing, thawing, mixing, and avoiding repeated freeze-thaw cycles. These rules should be validated or verified under the laboratory’s own conditions and then taught as routine practice.
Rejection criteria should be usable, not decorative
Every laboratory can list rejection criteria. Fewer laboratories apply them consistently when the ward is busy, the patient is difficult to recollect, or the clinician wants an urgent result. For coagulation testing, weak rejection practice creates downstream confusion. A questionable sample may generate a questionable result, and the discussion then shifts to interpretation instead of specimen quality.
Good rejection criteria are short, visible, and supported by management. They should cover common problems such as incorrect tube fill, clotted samples, unsuitable specimen type, excessive hemolysis or lipemia where method performance is affected, delayed processing outside the defined window, and missing collection information. The laboratory should also define how rejected samples are communicated so that recollection is not delayed by unclear wording.
What this means for OEM and localization projects
For IVD manufacturers and localization partners, preanalytical discipline belongs in the application package. A reagent insert can describe intended use and assay procedure, but field success also depends on specimen collection notes, sample stability expectations, interference information, rejection guidance, and troubleshooting language. These materials should be written for the operators who will actually use them, not only for regulatory files.
When TY Biological Engineering Co., Ltd. supports coagulation reagent development, OEM cooperation, localized production, instruments, cleaning solutions, and consumables, the practical question is not simply whether a reagent reacts correctly in a controlled evaluation. The question is whether the full workflow can survive daily clinical laboratory conditions. That includes the tube, the courier, the centrifuge, the refrigerator, the analyzer, the operator, and the documentation.
For laboratories, the message is equally direct. Improving specimen handling is one of the most cost-effective ways to improve coagulation testing. It reduces unnecessary troubleshooting, protects reagent credibility, supports cleaner lot comparisons, and helps clinicians trust the result. In plasma-based hemostasis testing, the sample is not a detail before the test. It is the first controlled step of the test.